| Literature DB >> 26471845 |
Lygia Vieira Lopes1, Fernando Miguel2, Helga Freitas3, António Tavares4, Salvador Pangui5, Clara Castro6, Gonçalo Forjaz Lacerda7, Adhemar Longatto-Filho8,9,10, Elisabete Weiderpass11,12,13,14, Lúcio Lara Santos15,16,17.
Abstract
BACKGROUND: It is expected that, by 2020, 15 million new cases of cancer will occur every year in the world, one million of them in Africa. Knowledge of cancer trends in African countries is far from adequate, and improvements in cancer prevention efforts are urgently needed. The aim of this study was to characterize breast cancer clinically and pathologically at presentation in Luanda, Angola; we additionally provide quality information that will be useful for breast cancer care planning in the country.Entities:
Mesh:
Year: 2015 PMID: 26471845 PMCID: PMC4608221 DOI: 10.1186/s12913-015-1092-9
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Number of breast cancer cases admitted and treated per year at IACC
Age (years) distribution according to stage of the disease
| Stage | n (%) | Mean | Median | Minimum | Maximum |
|---|---|---|---|---|---|
| 0 | 38 (2.1) | 45.5 | 46 | 25 | 75 |
| I | 65 (3.5) | 49.2 | 49 | 20 | 84 |
| II | 225 (12.2) | 48.4 | 47 | 24 | 81 |
| III | 998 (54.2) | 47.3 | 45 | 16 | 87 |
| IV | 35 (1.9) | 44.1 | 44 | 23 | 60 |
| unclassified | 482 (26.1) | 50.1 | 49 | 18 | 85 |
Demographic, clinical and pathological figures for women included in study
| Characteristics | n (%) |
|---|---|
| Age (years) | |
| 20-29 | 10 (4.4) |
| 30-39 | 37 (16.4) |
| 40-49 | 91 (40,4) |
| 50-59 | 47 (20.9) |
| 60-69 | 23 (10.2) |
| 70-79 | 12 (5.3) |
| 80-89 | 5 (2.2) |
| Median | 47 (range 25–89) |
| Parity | |
| Nulliparous | 7 (3.1) |
| Multiparous | 162 (72) |
| Without information | 56 (24.9) |
| Clinical presentation | |
| Mammograms alteration | 8 (3.6) |
| Lump (<5 cm) | 29 (12.9) |
| Mass (>5 cm) | 32 (14.2) |
| Nipple or skin retraction | 21(9.3) |
| Ulcer | 21(9.3) |
| Swelling and redness (inflammatory) | 13 (5.8) |
| Breast swelling with axillar lymph nodes | 101 (44.9) |
| Histhological Type | |
| Ductal carcinoma in situ | 2 (0.9) |
| Invasive ductal carcinoma | 184 (81.8) |
| Invasive lobullar carcinoma | 2 (0.9) |
| Medullary | 9 (4) |
| Papillary | 17 (7.6) |
| Squamous cell carcinoma | 1 (0.4) |
| Mucinous | 1 (0.4) |
| Sarcoma | 1 (0.4) |
| No classified | 8 (3.6) |
| Grade | |
| I | 45 (10.1) |
| II | 123 (54.7) |
| III | 57 (25.2) |
| Stage | |
| 0 | 2 (0.9) |
| I | 4 (1.8) |
| II | 44 (19.5) |
| III | 150 (66.7) |
| IV | 25 (11.1) |
Fig. 2Medical education of general doctors of municipal hospitals regarding breast cancer. Specific consent to publish the images was obtained from all individuals
Urgent actions needed for breast cancer program in Angola
| Task | Actions |
|---|---|
| Structural developments | Hospital-based cancer registries, as a crucial step in order to establish a population-based cancer registry in Luanda. |
| Capacity building and awareness | “Municipalities against cancer” a comprehensive educational program that includes general doctors, nurses and teachers. |
| Diagnosis | Early detection; |
| Proactive programme for early detection that includes clinical and ultrasound examination by municipal doctors. Introduction of the modified triple test score (MTTS); | |
| Tissue procurement (FNA and histology); | |
| Pathology diagnosis accuracy and determination of ER, PR, HER2 and KI-67 (protein) status by IHC. | |
| Treatment decision | Multidisciplinary integrated treatment team in order to provide the most comprehensive treatment plan. |
| Adequate treatment | Surgery: The best surgical treatment (Surgical oncology training); |
| Systemic therapy: drugs availability, affordability and uninterrupted supply, safe storage and preparation, adequate prescription and administration, management of side effects; | |
| Radiation therapy: to be included in breast treatment protocol, management of side effects related to radiation; | |
| Accessibility to cost-effective chemotherapy or radiation therapy, and palliative care. | |
| Follow-up | Shared and supported follow-up program including all levels of care and adequate registration of follow-up data. |
| Palliative care | Pain control and adequate management of end-of-life care. |
ER estrogen receptor, PR progesterone receptor, IHC immunohistochemistry, HER2 human epidermal growth factor receptor, KI-67 (protein) proliferation marker